Is ALDX or PALI more profitable?

Palisade Bio's return on equity of -33.47% beat Aldeyra Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aldeyra Therapeutics N/A -53.14% -34.94% Palisade Bio N/A -33.47% -31.79%

Does the media refer more to ALDX or PALI?

In the previous week, Aldeyra Therapeutics had 7 more articles in the media than Palisade Bio. MarketBeat recorded 10 mentions for Aldeyra Therapeutics and 3 mentions for Palisade Bio. Aldeyra Therapeutics' average media sentiment score of 0.83 beat Palisade Bio's score of -0.59 indicating that Aldeyra Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aldeyra Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Palisade Bio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative

Is ALDX or IKT more profitable?

Inhibikase Therapeutics' return on equity of -42.80% beat Aldeyra Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aldeyra Therapeutics N/A -53.14% -34.94% Inhibikase Therapeutics N/A -42.80% -40.58%

Does the media prefer VNDA or ALDX?

In the previous week, Aldeyra Therapeutics had 5 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 10 mentions for Aldeyra Therapeutics and 5 mentions for Vanda Pharmaceuticals. Aldeyra Therapeutics' average media sentiment score of 0.83 beat Vanda Pharmaceuticals' score of 0.00 indicating that Aldeyra Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vanda Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aldeyra Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AMRN or ALDX?

In the previous week, Aldeyra Therapeutics had 4 more articles in the media than Amarin. MarketBeat recorded 10 mentions for Aldeyra Therapeutics and 6 mentions for Amarin. Aldeyra Therapeutics' average media sentiment score of 0.83 beat Amarin's score of -0.22 indicating that Aldeyra Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amarin 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aldeyra Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, ALDX or NMRA?

Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aldeyra Therapeutics N/A N/A -$33.85M -$0.39 N/A Neumora Therapeutics N/A N/A -$236.93M -$1.23 N/A

Is ALDX or NMRA more profitable?

Aldeyra Therapeutics' return on equity of -53.14% beat Neumora Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aldeyra Therapeutics N/A -53.14% -34.94% Neumora Therapeutics N/A -242.28% -131.32%

Does the media favor ALDX or NMRA?

In the previous week, Neumora Therapeutics had 22 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 32 mentions for Neumora Therapeutics and 10 mentions for Aldeyra Therapeutics. Aldeyra Therapeutics' average media sentiment score of 0.83 beat Neumora Therapeutics' score of 0.24 indicating that Aldeyra Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aldeyra Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neumora Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Aldeyra Therapeutics (ALDX) Competitors

$1.55 +0.03 (+1.97%)

Closing price 08/25/2026 04:00 PM Eastern

Extended Trading

$1.54 -0.01 (-0.65%)

As of 06:21 AM Eastern

Compare

ALDX vs. PALI, IKT, VNDA, AMRN, and NMRA

Should you buy Aldeyra Therapeutics stock or one of its competitors? Aldeyra Therapeutics's main competitors and comparable companies include Palisade Bio (PALI), Inhibikase Therapeutics (IKT), Vanda Pharmaceuticals (VNDA), Amarin (AMRN), and Neumora Therapeutics (NMRA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Aldeyra Therapeutics compare to Palisade Bio?

Aldeyra Therapeutics (NASDAQ:ALDX) and Palisade Bio (NASDAQ:PALI) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

59.7% of Aldeyra Therapeutics shares are held by institutional investors. Comparatively, 11.8% of Palisade Bio shares are held by institutional investors. 11.8% of Aldeyra Therapeutics shares are held by company insiders. Comparatively, 0.1% of Palisade Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Palisade Bio's return on equity of -33.47% beat Aldeyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aldeyra Therapeutics	N/A	-53.14%	-34.94%
Palisade Bio	N/A	-33.47%	-31.79%

Aldeyra Therapeutics presently has a consensus target price of $5.50, indicating a potential upside of 254.84%. Palisade Bio has a consensus target price of $9.00, indicating a potential upside of 334.78%. Given Palisade Bio's stronger consensus rating and higher probable upside, analysts clearly believe Palisade Bio is more favorable than Aldeyra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aldeyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00

Palisade Bio has higher revenue and earnings than Aldeyra Therapeutics. Palisade Bio is trading at a lower price-to-earnings ratio than Aldeyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.39	N/A
Palisade Bio	$250K	1,442.96	-$16.78M	-$0.48	N/A

Aldeyra Therapeutics has a beta of 1.21, suggesting that its share price is 21% more volatile than the broader market. Comparatively, Palisade Bio has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market.

In the previous week, Aldeyra Therapeutics had 7 more articles in the media than Palisade Bio. MarketBeat recorded 10 mentions for Aldeyra Therapeutics and 3 mentions for Palisade Bio. Aldeyra Therapeutics' average media sentiment score of 0.83 beat Palisade Bio's score of -0.59 indicating that Aldeyra Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aldeyra Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Palisade Bio	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Summary

Palisade Bio beats Aldeyra Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Aldeyra Therapeutics compare to Inhibikase Therapeutics?

Aldeyra Therapeutics (NASDAQ:ALDX) and Inhibikase Therapeutics (NASDAQ:IKT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Aldeyra Therapeutics has higher earnings, but lower revenue than Inhibikase Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Aldeyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.39	N/A
Inhibikase Therapeutics	$260K	1,341.73	-$48.26M	-$0.43	N/A

Aldeyra Therapeutics currently has a consensus price target of $5.50, indicating a potential upside of 254.84%. Inhibikase Therapeutics has a consensus price target of $5.40, indicating a potential upside of 116.00%. Given Aldeyra Therapeutics' higher possible upside, analysts clearly believe Aldeyra Therapeutics is more favorable than Inhibikase Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aldeyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.00

Aldeyra Therapeutics has a beta of 1.21, meaning that its stock price is 21% more volatile than the broader market. Comparatively, Inhibikase Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market.

Inhibikase Therapeutics' return on equity of -42.80% beat Aldeyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aldeyra Therapeutics	N/A	-53.14%	-34.94%
Inhibikase Therapeutics	N/A	-42.80%	-40.58%

59.7% of Aldeyra Therapeutics shares are held by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are held by institutional investors. 11.8% of Aldeyra Therapeutics shares are held by company insiders. Comparatively, 7.1% of Inhibikase Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Aldeyra Therapeutics had 9 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 10 mentions for Aldeyra Therapeutics and 1 mentions for Inhibikase Therapeutics. Aldeyra Therapeutics' average media sentiment score of 0.83 beat Inhibikase Therapeutics' score of 0.00 indicating that Aldeyra Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aldeyra Therapeutics	Positive
Inhibikase Therapeutics	Neutral

Summary

Aldeyra Therapeutics beats Inhibikase Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Aldeyra Therapeutics compare to Vanda Pharmaceuticals?

Vanda Pharmaceuticals (NASDAQ:VNDA) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

Vanda Pharmaceuticals has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market. Comparatively, Aldeyra Therapeutics has a beta of 1.21, indicating that its share price is 21% more volatile than the broader market.

Vanda Pharmaceuticals currently has a consensus target price of $13.70, indicating a potential upside of 151.84%. Aldeyra Therapeutics has a consensus target price of $5.50, indicating a potential upside of 254.84%. Given Aldeyra Therapeutics' higher probable upside, analysts clearly believe Aldeyra Therapeutics is more favorable than Vanda Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Aldeyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are owned by institutional investors. 10.7% of Vanda Pharmaceuticals shares are owned by company insiders. Comparatively, 11.8% of Aldeyra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Aldeyra Therapeutics had 5 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 10 mentions for Aldeyra Therapeutics and 5 mentions for Vanda Pharmaceuticals. Aldeyra Therapeutics' average media sentiment score of 0.83 beat Vanda Pharmaceuticals' score of 0.00 indicating that Aldeyra Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vanda Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aldeyra Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aldeyra Therapeutics has lower revenue, but higher earnings than Vanda Pharmaceuticals. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vanda Pharmaceuticals	$216.10M	1.52	-$220.47M	-$4.63	N/A
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.39	N/A

Aldeyra Therapeutics has a net margin of 0.00% compared to Vanda Pharmaceuticals' net margin of -127.41%. Vanda Pharmaceuticals' return on equity of -49.81% beat Aldeyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vanda Pharmaceuticals	-127.41%	-49.81%	-33.29%
Aldeyra Therapeutics	N/A	-53.14%	-34.94%

Summary

Aldeyra Therapeutics beats Vanda Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Aldeyra Therapeutics compare to Amarin?

Amarin (NASDAQ:AMRN) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation.

In the previous week, Aldeyra Therapeutics had 4 more articles in the media than Amarin. MarketBeat recorded 10 mentions for Aldeyra Therapeutics and 6 mentions for Amarin. Aldeyra Therapeutics' average media sentiment score of 0.83 beat Amarin's score of -0.22 indicating that Aldeyra Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amarin	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aldeyra Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amarin has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market. Comparatively, Aldeyra Therapeutics has a beta of 1.21, suggesting that its share price is 21% more volatile than the broader market.

Aldeyra Therapeutics has lower revenue, but higher earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than Aldeyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$213.65M	1.40	-$38.80M	-$0.99	N/A
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.39	N/A

Amarin currently has a consensus price target of $13.00, indicating a potential downside of 8.13%. Aldeyra Therapeutics has a consensus price target of $5.50, indicating a potential upside of 254.84%. Given Aldeyra Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aldeyra Therapeutics is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33
Aldeyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Aldeyra Therapeutics has a net margin of 0.00% compared to Amarin's net margin of -14.56%. Amarin's return on equity of -0.20% beat Aldeyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amarin	-14.56%	-0.20%	-0.14%
Aldeyra Therapeutics	N/A	-53.14%	-34.94%

22.3% of Amarin shares are owned by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are owned by institutional investors. 4.2% of Amarin shares are owned by insiders. Comparatively, 11.8% of Aldeyra Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Aldeyra Therapeutics beats Amarin on 12 of the 15 factors compared between the two stocks.

How does Aldeyra Therapeutics compare to Neumora Therapeutics?

Aldeyra Therapeutics (NASDAQ:ALDX) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.

Aldeyra Therapeutics has a beta of 1.21, indicating that its share price is 21% more volatile than the broader market. Comparatively, Neumora Therapeutics has a beta of 2.75, indicating that its share price is 175% more volatile than the broader market.

In the previous week, Neumora Therapeutics had 22 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 32 mentions for Neumora Therapeutics and 10 mentions for Aldeyra Therapeutics. Aldeyra Therapeutics' average media sentiment score of 0.83 beat Neumora Therapeutics' score of 0.24 indicating that Aldeyra Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aldeyra Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neumora Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

59.7% of Aldeyra Therapeutics shares are held by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are held by institutional investors. 11.8% of Aldeyra Therapeutics shares are held by insiders. Comparatively, 26.9% of Neumora Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.39	N/A
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.23	N/A

Aldeyra Therapeutics' return on equity of -53.14% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aldeyra Therapeutics	N/A	-53.14%	-34.94%
Neumora Therapeutics	N/A	-242.28%	-131.32%

Aldeyra Therapeutics currently has a consensus price target of $5.50, indicating a potential upside of 254.84%. Neumora Therapeutics has a consensus price target of $6.57, indicating a potential upside of 338.10%. Given Neumora Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Neumora Therapeutics is more favorable than Aldeyra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aldeyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Neumora Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60

Summary

Neumora Therapeutics beats Aldeyra Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Aldeyra Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALDX vs. The Competition

Export

Metric	Aldeyra Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$91.70M	$12.52B	$7.34B	$12.72B
Dividend Yield	N/A	2.61%	2.53%	10.79%
P/E Ratio	-3.97	778.15	271.01	24.15
Price / Sales	N/A	758.07	627.95	102.20
Price / Cash	N/A	98.02	78.57	53.12
Price / Book	2.46	12.01	13.14	6.25
Net Income	-$33.85M	$2.80B	$3.46B	$347.86M
7 Day Performance	-1.90%	2.85%	1.51%	0.98%
1 Month Performance	1.97%	6.52%	8.81%	5.24%
1 Year Performance	-73.68%	8.04%	26.07%	17.04%

Aldeyra Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALDX Aldeyra Therapeutics	3.7606 of 5 stars	$1.55 +2.0%	$5.50 +254.8%	-73.1%	$91.70M	N/A	N/A	10	Gap Up
PALI Palisade Bio	2.3645 of 5 stars	$2.15 +0.5%	$9.00 +318.6%	+199.9%	$372.94M	$250K	N/A	10
IKT Inhibikase Therapeutics	1.653 of 5 stars	$2.39 -0.8%	$5.40 +125.9%	N/A	$336.28M	$260K	N/A	6
VNDA Vanda Pharmaceuticals	2.1615 of 5 stars	$5.26 +0.8%	$13.70 +160.5%	+18.0%	$315.61M	$216.10M	N/A	290
AMRN Amarin	0.8996 of 5 stars	$14.01 -0.4%	N/A	-8.1%	$297.20M	$213.65M	N/A	360	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALDX) was last updated on 8/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aldeyra Therapeutics (ALDX) Competitors

ALDX vs. PALI, IKT, VNDA, AMRN, and NMRA

How does Aldeyra Therapeutics compare to Palisade Bio?

Summary

How does Aldeyra Therapeutics compare to Inhibikase Therapeutics?

Summary

How does Aldeyra Therapeutics compare to Vanda Pharmaceuticals?

Summary

How does Aldeyra Therapeutics compare to Amarin?

Summary

How does Aldeyra Therapeutics compare to Neumora Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALDX vs. The Competition

Aldeyra Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aldeyra Therapeutics (ALDX) Competitors

ALDX vs. PALI, IKT, VNDA, AMRN, and NMRA

How does Aldeyra Therapeutics compare to Palisade Bio?

Do institutionals and insiders have more ownership in ALDX or PALI?

Is ALDX or PALI more profitable?

Do analysts rate ALDX or PALI?

Which has higher valuation and earnings, ALDX or PALI?

Which has more risk & volatility, ALDX or PALI?

Does the media refer more to ALDX or PALI?

Summary

How does Aldeyra Therapeutics compare to Inhibikase Therapeutics?

Which has higher earnings and valuation, ALDX or IKT?

Do analysts prefer ALDX or IKT?

Which has more risk & volatility, ALDX or IKT?

Is ALDX or IKT more profitable?

Do institutionals & insiders believe in ALDX or IKT?

Does the media refer more to ALDX or IKT?

Summary

How does Aldeyra Therapeutics compare to Vanda Pharmaceuticals?

Which has more volatility & risk, VNDA or ALDX?

Do analysts prefer VNDA or ALDX?

Do insiders & institutionals have more ownership in VNDA or ALDX?

Does the media prefer VNDA or ALDX?

Which has better earnings & valuation, VNDA or ALDX?

Is VNDA or ALDX more profitable?

Summary

How does Aldeyra Therapeutics compare to Amarin?

Does the media prefer AMRN or ALDX?

Which has more risk & volatility, AMRN or ALDX?

Which has better valuation and earnings, AMRN or ALDX?

Do analysts recommend AMRN or ALDX?

Is AMRN or ALDX more profitable?

Do insiders and institutionals have more ownership in AMRN or ALDX?

Summary

How does Aldeyra Therapeutics compare to Neumora Therapeutics?

Which has more risk & volatility, ALDX or NMRA?

Does the media favor ALDX or NMRA?

Do insiders & institutionals believe in ALDX or NMRA?

Which has stronger valuation & earnings, ALDX or NMRA?

Is ALDX or NMRA more profitable?

Do analysts rate ALDX or NMRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALDX vs. The Competition

Aldeyra Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools